In a report released today, Vamil Divan from Mizuho Securities maintained a Buy rating on Magenta Therapeutics (MGTA – Research Report), with a price target of $8.00. The company’s shares closed last Thursday at $2.24.
According to TipRanks.com, Divan is a 2-star analyst with an average return of 0.6% and a 50.8% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Magenta Therapeutics is a Strong Buy with an average price target of $7.00.
Magenta Therapeutics’ market cap is currently $141.7M and has a P/E ratio of -1.85.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.
Read More on MGTA:
- Wedbush Maintains a Hold Rating on US Bancorp (USB)
- Charter Equity Keeps a Hold Rating on Telefonaktiebolaget LM Ericsson (ERIC)
- Raymond James Maintains Their Buy Rating on SilverCrest Metals (SILV)
- Osisko Mining (OBNNF) Gets a Buy Rating from Raymond James
- National Bank Keeps a Buy Rating on Air Canada (ACDVF)